321 related articles for article (PubMed ID: 23125448)
1. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
Steele J; Mukherjee J; Parry N; Tzipori S
J Infect Dis; 2013 Jan; 207(2):323-30. PubMed ID: 23125448
[TBL] [Abstract][Full Text] [Related]
2. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.
Steele J; Parry N; Tzipori S
Gut Microbes; 2014; 5(1):53-7. PubMed ID: 24394234
[TBL] [Abstract][Full Text] [Related]
3. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
[TBL] [Abstract][Full Text] [Related]
4. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
[TBL] [Abstract][Full Text] [Related]
5. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
[TBL] [Abstract][Full Text] [Related]
6. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
[TBL] [Abstract][Full Text] [Related]
7. Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.
Hussack G; Tanha J
Toxins (Basel); 2010 May; 2(5):998-1018. PubMed ID: 22069622
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
[TBL] [Abstract][Full Text] [Related]
9. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
[TBL] [Abstract][Full Text] [Related]
10. Mouse relapse model of Clostridium difficile infection.
Sun X; Wang H; Zhang Y; Chen K; Davis B; Feng H
Infect Immun; 2011 Jul; 79(7):2856-64. PubMed ID: 21576341
[TBL] [Abstract][Full Text] [Related]
11. Protective efficacy induced by recombinant Clostridium difficile toxin fragments.
Leuzzi R; Spencer J; Buckley A; Brettoni C; Martinelli M; Tulli L; Marchi S; Luzzi E; Irvine J; Candlish D; Veggi D; Pansegrau W; Fiaschi L; Savino S; Swennen E; Cakici O; Oviedo-Orta E; Giraldi M; Baudner B; D'Urzo N; Maione D; Soriani M; Rappuoli R; Pizza M; Douce GR; Scarselli M
Infect Immun; 2013 Aug; 81(8):2851-60. PubMed ID: 23716610
[TBL] [Abstract][Full Text] [Related]
12. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
[TBL] [Abstract][Full Text] [Related]
13. Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile.
Steele J; Sponseller J; Schmidt D; Cohen O; Tzipori S
Hum Vaccin Immunother; 2013 Jul; 9(7):1565-8. PubMed ID: 23435084
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.
Donald RGK; Flint M; Kalyan N; Johnson E; Witko SE; Kotash C; Zhao P; Megati S; Yurgelonis I; Lee PK; Matsuka YV; Severina E; Deatly A; Sidhu M; Jansen KU; Minton NP; Anderson AS
Microbiology (Reading); 2013 Jul; 159(Pt 7):1254-1266. PubMed ID: 23629868
[TBL] [Abstract][Full Text] [Related]
15. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
[TBL] [Abstract][Full Text] [Related]
16. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
[TBL] [Abstract][Full Text] [Related]
17. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.
Maynard-Smith M; Ahern H; McGlashan J; Nugent P; Ling R; Denton H; Coxon R; Landon J; Roberts A; Shone C
Vaccine; 2014 Feb; 32(6):700-5. PubMed ID: 24342251
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain.
Hussack G; Arbabi-Ghahroudi M; van Faassen H; Songer JG; Ng KK; MacKenzie R; Tanha J
J Biol Chem; 2011 Mar; 286(11):8961-76. PubMed ID: 21216961
[TBL] [Abstract][Full Text] [Related]
19. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.
Steele J; Chen K; Sun X; Zhang Y; Wang H; Tzipori S; Feng H
J Infect Dis; 2012 Feb; 205(3):384-91. PubMed ID: 22147798
[TBL] [Abstract][Full Text] [Related]
20. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]